For example, tyrosine kinase inhibitors (TKIs) can effectively target Philadelphia chromosome-positive ALL, while immunotherapies that target CD19 have shown promise in treating B-cell ALL [13]. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.